Search - tctmd.com

Displaying 401 - 420 of 2043

Sort: Relevancy | Date

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

Todd Neale

November 13, 2023

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

Presentation AHA 2023

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Presenter: Alexander C. Fanaroff

November 13, 2023

News Conference News AHA 2023

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

L.A. McKeown

November 13, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

Todd Neale

November 11, 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP-Lowering KARDIA-1

News Conference News AHA 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Caitlin E. Cox

November 11, 2023

Presentation AHA 2023

Safety and Pharmacodynamic Effects of VERVE-101

Presenter: Andrew Bellinger

November 11, 2023

Presentation AHA 2023

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

November 11, 2023

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Daily News

Very High LDL Cholesterol Declines in US Adults, but Progress Is Slow

Michael O'Riordan

November 02, 2023

News Opinion CV Team Dispatch

November 2023 News Roundup

L.A. McKeown

November 01, 2023

News Conference News TCT 2023

RADIANCE: 'Modest' Renal Denervation Effect Remains at 6 Months

Todd Neale

October 31, 2023

News Daily News

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Yael L. Maxwell

October 19, 2023

News Conference News HFSA 2023

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

L.A. McKeown

October 18, 2023

News Conference News EACTS 2023

Combined Surgical and Catheter Ablation Best for Persistent AF

Michael O'Riordan

October 12, 2023

Advertisement

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Safety and Pharmacodynamic Effects of VERVE-101

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

FDA Grants Tirzepatide a New Indication for Obesity Management

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

What’s Going to Be Hot at AHA 2023

Very High LDL Cholesterol Declines in US Adults, but Progress Is Slow

November 2023 News Roundup

RADIANCE: 'Modest' Renal Denervation Effect Remains at 6 Months

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

Combined Surgical and Catheter Ablation Best for Persistent AF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content